PerkinElmer launches new version of imaging acquisition, analysis software

PerkinElmer launched its Volocity 5 imaging software suite, developed by its subsidiary Improvision, last week at the Society for Neuroscience conference in Washington, D.C.

The Waltham, Mass.-based PerkinElmer said its Volocity 5 software is designed for 3D and 4D image acquisition, allowing data visualization, deconvolution, publication, object measurement, tracking and charting. Using Volocity, cell images can either be acquired or the data imported from a diverse range of fluorescence microscopy systems. Acquired images are then analyzed in 3D and 4D, delivering both qualitative and quantitative information. 

The Volocity suite comprises four core software products, all of which are available for Windows and Mac OS:
  • Volocity Acquisition: Designed for high-speed image capture, ranging from 2D image capture to multi-channel 4D experiments;
  • Volocity Visualization: For interactive high-resolution 4D rendering of multi-channel 3D and 4D data sets;
  • Volocity Quantitation: For measurement, tracking and analysis structure and function in 3D and 4D image data; and
  • Volocity Restoration: For conversion of fluorescence microscope images into confocal quality data.
The company said the features of Volocity 5 include: a new library view; updated renderer; image and slice views; user-specified XY dimensions; and Windows Vista and Mac OS X user interface.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.